Key points
-
The establishment, regular review and use of Diagnostic Reference Levels are mandatory according to the Council Directive 2013/59/EURATOM.
-
Most of the existing Diagnostic Reference Levels have been established based on anatomical locations, which has some limitations as one could have several clinical indications with consequently different protocols corresponding to different exposure levels.
-
In the anatomical areas for which Diagnostic Reference Levels based on clinical indications were found, a huge variation of computed tomography dose descriptors values has been identified.
-
The EUCLID project aims to establish Diagnostic Reference Levels based on clinical indications.
Background
The concept of Diagnostic Reference Levels (DRLs) was introduced many years ago by the International Commission on Radiological Protection (ICRP) [1] and has been widely accepted as a practical tool for optimisation in diagnostic and interventional radiology and nuclear medicine. DRLs should be used as a form of investigation level to identify unusually high dose levels. If DRLs are consistently exceeded, a local review usually takes place. DRLs are not intended for regulatory or commercial purposes, nor do they represent a dose constraint, nor are they linked to limits or constraints [2].
Anzeige
The European Union has formally introduced the concept and the mandatory use of DRLs in every Member State since 1997 [3], reinforcing the obligation for the establishment, regular review and use in 2013 through the Council Directive 2013/59/EURATOM (BSSD), on health protection of individuals against the dangers of ionising radiation in relation to medical exposure [4].
Most of the existing DRLs (independently of the imaging modality) have been established based on anatomical locations. However, some limitations of this approach were pointed out for computed tomography (CT) as, for the same anatomical location, one could have several clinical indications with consequently different protocols corresponding to different exposure levels. For example, chest CT could correspond to the work-up for pulmonary embolism, lung cancer, or even coronary calcium scoring, each of which requires corresponding image quality parameters and scan length, and hence should have different DRLs [5].
The clinical approach to DRLs was mentioned some years ago by the ICRP [6], but most of the European National Competent Authorities (NCAs) still consider DRLs for anatomical location and not for clinical indication. However, some countries have recently established DRL based on clinical indications (DRLci) and some others are planning to do so in the near future. Also the European Society of Radiology (ESR) EuroSafe Imaging Call for Action 2018 has defined the objective to develop DRLci for adults and children, under action number 2 [7].
In this work, the dose descriptors used to define a DRL in CT are (a) volume computed tomography dose index (CTDIvol), the standard descriptor for estimating the output dose of a CT scanner, based on measurements obtained when scanning either a 16 cm or 32 cm phantom [8] and the unit used is mGy; (b) dose length product total (DLPt), which is the sum of the DLP values from each CT acquisition/phase, representing the measure of the total amount of radiation used to perform the CT examination. DLP is the product of the CTDIvol (mGy) and scan length (cm), and the unit used is mGy.cm.
Anzeige
Both CTDIvol and DLPt are essential tools for CT optimisation; however it is important to understand the fact that they only represent CT scanner output and consequently are not patient dose estimates [9].
In August 2017, the European Commission (EC) launched the “European Study on Clinical Diagnostic Reference Levels for X-ray Medical Imaging” (EUCLID) project, to provide up-to-date DRLCI.
The main objectives of the EUCLID project, led by the ESR, were to conduct a European survey to collect data needed for the establishment of DRLci for the most important X-ray imaging tasks in Europe (from the radiation protection perspective) and to specify up-to-date DRLci for those examinations.
The aim of this work was to conduct an extensive literature review by analysing the most recent studies published and the data provided by NCAs, to understand the current situation regarding DRLci for CT, under the scope of EUCLID project.
Materials and methods
One of the goals of EUCLID was the collection of information on the status of national DRLs and DRLci in Europe from NCAs from literature and from a workshop held in December 2019 in Luxembourg. The methodology for this included contacting the NCAs of 31 European countries and asking them to provide available national data that was then discussed and confirmed during the aforementioned workshop. Additionally, a comprehensive literature review was undertaken in order to identify which clinical indications had already been specifically studied.
To perform the literature review, several databases were used, such as science direct, PubMed and Google Scholar. Multiple keywords combination was used, such as diagnostic reference levels in computed tomography, clinical diagnostic reference levels and diagnostic reference levels based on clinical indications. All publications were collected and stored in the Mendeley reference management software (www.mendeley.com).
Results
Literature review for DRLci in CT
By using the keywords defined, data from 65 papers was considered and amongst them 23 included DRLci, being that 3 of them were from countries outside Europe (United States of America, Japan and Egypt) and 12 from European countries: Austria, Denmark, Finland, France, Germany, Ireland, Italy, Norway, Sweden, Switzerland, The Netherlands, United Kingdom. In addition, data provided by the NCAs, discussed and validated during the workshop, were also included.
Considering that the concept of DRLci is a recent one, some discrepancy and inconsistency was found in the classification of the clinical indication.
Anzeige
The DRLci values found were for several anatomical areas and are listed in Table 1. A total of 28 clinical indications for 6 anatomical areas have been identified. The anatomical areas with the most values for DRLci were “head” and “abdomen”, with a total of 6 each.
Table 1
CT clinical indications
Anatomical area | Clinical indication |
|---|---|
Head: nci 6 | Acute stroke |
Haemorrhage/aneurysms/arteriovenous malformations | |
Metastases/cerebral abscess | |
Trauma | |
Cholesteatoma | |
Sinusitis | |
Cervical (spine and neck): nci 3 | Fracture |
Disk pathology | |
Adenopathy/abscesses | |
Chest: nci 5 | Lung cancer |
Interstitial lung disease | |
Pulmonary embolism | |
Coronaries (CTC angiography) | |
Coronaries (calcium scoring) | |
Abdomen: nci 6 | Liver metastases |
Abscess | |
Kidney stones/colic | |
Kidney tumour/colic | |
Acute abdomen | |
Pancreas adenocarcinoma | |
Abdomen-pelvis: nci 5 | Abscess/lymphadenopathy |
Virtual colonoscopy (polyps/tumour) | |
Abdominal aorta angiography | |
Colic | |
Occlusion | |
Chest-abdomen-pelvis: nci 3 | Tumour |
Infectious | |
Oncologic follow-up |
Head CT
For head CT, 10 references with DRLci were found for 6 clinical indications: acute stroke; haemorrhage/aneurysms/arteriovenous malformations; metastases/cerebral abscess; trauma; cholesteatoma; sinusitis. Table 2 shows the DRLci for head CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for trauma/sinusitis was the clinical indication with the most references found (7 out of 10). The DLP values ranged from 90 mGy.cm [14] to 1000 mGy.cm [18]. One publication presents DRLci for head CT both for males and females [16], demonstrating however similar or in some cases equal values.
Table 2
DRLci for head CT
Head CT | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Acute stroke/post fossa | Acute stroke/cerebrum | Acute stroke/brain (whole) | Acute stroke/all sequences | Haemorrhage, aneurysms, arteriovenous malformations | Metastases, cerebral abscess | Trauma, sinusitis | Cholesteatoma | Sinusitis | |||||||||
CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | |
Danish Health Authority (DK) 2015 [10] | – | – | – | – | – | – | – | – | 58 | 930 | – | – | – | – | – | – | – | – |
Public Health England (UK) 2016 [11] | 80 | – | 60 | – | 60 | – | – | 970 | – | – | – | – | – | – | – | – | – | – |
Schegerer et al. (DE) 2017 [12] | – | – | – | – | – | – | – | – | – | – | – | – | 9 | 120 | – | – | – | – |
Treier et al. (CH) 2010 (22) | – | – | – | – | – | – | – | – | 65 | 1000 | 65 | 1000 | 25 | 350 | 50 | 250 | – | – |
Van der Molen et al. (NL) 2013 [13] | – | – | – | – | – | – | – | – | – | 936 | – | – | – | 133 | – | – | – | – |
Wachabauer et al. (AT) 2017 [14] | – | – | – | – | – | – | – | – | – | – | – | – | – | 90 | – | – | – | – |
Geryes et al. (FR) 2019 [15] | – | – | – | – | – | – | – | – | 44 | 1010 | 44 | 790 | 43 | 920 | – | – | – | – |
Ireland (IE) MERU 2017 [16] | 26 (a) | 469 (a) | – | – | – | – | – | – | – | – | – | – | 62 (a) | 918 (a) | – | – | 21 (a) | 183 (a) |
31 (b) | 477 (b) | – | – | – | – | – | – | – | – | – | – | 64 (b) | 927 (b) | – | – | 21 (b) | 210 (b) | |
Norway (NO) 2018 [17] | – | – | – | – | – | – | 60 | 950 | 60 | 950 | – | – | – | – | – | – | – | – |
Sweden (SE) 2019 [18] | – | – | – | – | – | – | 60 | 1000 | 60 | 1000 | – | – | 60 | 1000 | – | – | – | - |
Cervical (spine and neck) CT
For cervical (spine and neck) CT, eight references with DRLci were found for three clinical indications: fracture, disk pathology and adenopathy/abscess. Table 3 shows the DRLci for cervical (spine and neck) CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for fracture was the clinical indication with more references found (six out of eight). The DLP values ranged from 300 mGy.cm [18] to 640 mGy.cm [15]. One publication presents DRLci for head CT both for males and females [16], however, with similar values. Two publications from the same country, one from 2016 [11] and other from 2018 [19], show a reduction of DLP values from 600 mGy.cm to 440 mGy.cm for the same clinical indication “fracture”.
Table 3
DRLci for cervical CT
Cervical CT | ||||||
|---|---|---|---|---|---|---|
References | Fracture | Disk pathology | Adenopathy, abscesses | |||
CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | |
Schegerer et al. (DE) 2019 [20] | 20 | – | 25 | – | – | – |
Public Health England (UK) 2016 [11] | 26 | 600 | – | – | – | – |
Treier et al. (CH) 2010 [21] | – | – | – | – | 30 | 600 |
Geryes et al. (FR) 2019 [15] | 31 | 640 | – | – | – | – |
Ireland (IE) MERU 2017 [16] | 26 (a) | 469 (a) | – | – | – | – |
31 (b) | 477 (b) | – | – | – | – | |
Norway (NO) 2018 [17] | 15 | 350 | – | – | – | – |
Sweden (SE) 2019 [18] | 13 | 300 | – | – | 30 | 600 |
Public Health England (UK) 2018 [19] | 21 | 440 | – | – | – | – |
Chest CT
For chest CT, 23 references with DRLci were found for 6 clinical indications: lung cancer, interstitial lung disease, pulmonary embolism, coronary computed tomography angiography (CCTA), calcium scoring. Table 4 shows the DRLci for chest CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for CCTA was the clinical indication with more references found (11 out of 23). The DLP values ranged from 170 mGy.cm [12] to 1400 mGy.cm [22]. One publication presents DRLci for CCTA [12] made with three different approaches: prospective, no padding, 170 mGy.cm (c); prospective, with padding, 280 mGy.cm (d); prospective, with gating, 380 mGy.cm (e). From the three approaches, the prospective, no padding technique is the one that provides the lowest DLP value (170 mGy.cm).
Table 4
DRLci for chest CT
Chest CT | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Lung cancer | Interstitial lung disease (axial) | Interstitial lung disease (helical) | Pulmonary embolism | CCTA | Calcium scoring | ||||||
ctdivol (mgy) | dlp (mgy.cm) | ctdivol (mgy) | dlp (mgy.cm) | ctdivol (mgy) | dlp (mgy.cm) | ctdivol (mgy) | dlp (mgy.cm) | ctdivol (mgy) | dlp (mgy.cm) | ctdivol (mgy) | dlp (mgy.cm) | |
Castellano et al. (UK) 2017 [22] | – | – | – | – | – | – | – | – | – | 173 | – | – |
Danish Health Authority (DK) 2015 [10] | 16 | 620 | – | – | 13 | 500 | – | – | 29 | 230 | – | – |
Foley et al. (IE) 2012 [23] | – | – | 7 | 276 | – | – | 13 | 432 | – | – | – | – |
Fukushima et al. (JP) 2012 [24] | – | – | – | – | – | – | – | – | – | 1510 | – | |
Schegerer et al. (DE) 2019 [20] | – | – | – | – | – | – | – | – | 20 | 330 (d) | – | |
Hausleiter et al. 2009 [25] | – | – | – | – | – | – | – | – | 69,6 | 1152 | – | |
Japan Network for Research on Medical Exposures (JP) 2015 [26] | – | – | – | – | – | – | – | – | 90 | 1400 | – | – |
Kanal et al. (USA) 2017 [27] | – | – | – | – | – | – | 19 | 557 | – | – | – | – |
Mafalanka et al. (FR) 2015 [28] | – | – | – | – | – | – | – | – | – | 870 | – | – |
Palorini et al. (IT) 2014 [29] | – | – | – | – | – | – | – | – | – | 1208 | – | 131 |
Public Health England (UK) 2016 [11] | 12 | 610 | 4 | 140 | 12 | 350 | 13 | 440 | – | – | – | – |
Radiation and Nuclear Safety Authority (FI) 2013 [30] | 11 | 430 | – | – | – | – | – | – | – | – | – | – |
Salama et al. (EG) 2017 [31] | – | – | – | – | 22 | 421 | – | – | – | – | – | – |
Schegerer et al. (DE) 2017 [12] | – | – | – | – | – | – | 15 | 300 | 36 (e) 19 (d) | 551 (e) 270 (d) | 8 | 119 |
Treier et al. (CH) 2010 [21] | – | – | – | – | – | – | – | – | – | 1000 | – | 150 |
Van der Molen et al. (NL) 2013 [13] | – | – | – | – | – | 276 | – | 371 | – | 671 | – | 51 |
Wachabauer et al. (AT) 2017 [14] | – | – | – | – | – | – | – | 400 | – | – | – | – |
Geryes et al. (FR) 2019 [15] | – | – | – | – | – | – | 8 | 310 | – | – | – | – |
Ireland (IE) MERU 2017 [16] | 7 (a) | 241 (a) | – | – | 7 (a) | 210 (a) | 9 (a) | 234 (a) | – | – | – | – |
7 (b) | 272 (b) | – | – | 7 (b) | 249 (b) | 12 (b) | 278 (b) | – | – | – | – | |
Norway (NO) 2018 [17] | 9 | 350 | – | – | 9 | 300 | – | – | – | – | – | – |
Sweden (SE) 2019 [18] | 9 | 350 | – | – | – | – | – | – | – | – | – | |
Public Health England (UK) 2018 [19] | – | – | – | – | – | – | – | – | – | 170 (c) | – | – |
– | – | – | – | – | – | – | – | – | 280 (d) | – | – | |
– | – | – | – | – | – | – | – | – | 380 (e) | – | – | |
Netherlands (NL) 2012 [32] | – | – | – | – | – | – | 10 | 350 | – | – | – | – |
Anzeige
Abdominal CT
For abdominal CT, 11 references with DRLci were found for 6 clinical indications: liver metastasis, abscess, kidney stones/colic, kidney tumour/colic, acute abdomen and pancreas adenocarcinoma. Table 5 shows the DRLci for abdominal CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for liver metastasis and kidney stone/colic were the clinical indications with more references found (6 out of 12). For liver metastasis, the DLP values ranged from 400 mGy.cm [15, 19] to 1423 mGy.cm [27]. For kidney stone/colic, the DLP values ranged from 200 mGy.cm [33] to 460 mGy.cm [18]. One publication presents DRLci for abdominal CT, both for males and females [16], demonstrating however similar values.
Table 5
DRLci for abdominal CT
Abdomen | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reference | Liver metastases | Abscess | Kidney stones/colic | Kidney tumour/colic | Acute abdomen | Pancreas adeno Ca | ||||||
CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | |
Danish Health Authority (DK) 2015 [10] | – | – | – | – | – | – | – | – | 17 | 700 | – | – |
Public Health England (UK) 2016 [11] | 14 | 910 | 15 | 745 | 10 | 460 | 13 | 1150 | – | – | – | – |
Radiation and Nuclear Safety Authority (FI) 2013 [30] | – | – | – | – | 7 | 330 | – | – | – | – | – | – |
Salama et al. (EG) 2017 [31] | 31 | 1423 | – | – | – | – | – | – | – | – | – | – |
Treier et al. (CH) 2010 [21] | 15 | 400 | – | – | – | – | – | – | – | –– | – | – |
Van der Molen et al. (NL) 2013 [13] | – | – | – | – | – | 329 | – | 1371 | – | – | – | 1000 |
Wachabauer et al. (AT) 2017 [14] | – | 400 | – | – | – | – | – | – | – | – | – | – |
Ireland (IE) MERU 2017 [16] | 9 (a) | 554 (a) | – | – | 6 (a) | 254 (a) | – | – | – | – | – | – |
10 (b) | 515 (b) | – | – | 8 (b) | 291 (b) | – | – | – | – | – | – | |
Norway (NO) 2018 [17] | – | – | – | – | 5 | 250 | 13 | 1300 | – | – | – | – |
Sweden (SE) 2019 [18] | 11 | 550 | – | – | 5 | 200 | 12 | 1000 | – | – | – | – |
Netherlands (NL) 2012 [32] | – | – | – | – | – | – | – | – | 15 | 700 | – | – |
Abdominopelvic CT
For abdominopelvic CT, five references with DRLci were found for five clinical indications: abscess/lymphadenopathy, virtual colonoscopy (VC)/polyps/tumour, CT for abdominal aortic aneurysms (AAA), colic and occlusion. Table 6 shows the DRLci for abdominopelvic CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for abscess/lymphadenopathy was the clinical indication with more references found (four out of five). The DLP values ranged from 650 mGy.cm [11, 15, 34] to 750 mGy.cm [18].
Table 6
DRLci for abdomino-pelvis CT
Abdomino-pelvis CT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
References | Abscess lymphadenopathy | VC-polyps/tumour | CT angiography (AAA) | Colic | Occlusion | |||||
CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | |
Public Health England (UK) 2016 [11] | 15 | 745 | 11 | 950 | – | – | – | – | – | – |
Treier et al. (CH) 2010 [21] | 15 | 650 | – | – | 15 | 650 | – | – | – | – |
Van der Molen et al. (NL) 2013 [13] | – | – | – | – | – | 727 | – | – | – | – |
Wachabauer et al. (AT) 2017 [14] | – | 650 | – | – | – | – | – | – | – | – |
Geryes et al. (FR) 2019 [15] | – | 650 | – | – | – | – | 8 | 400 | 12 | 880 |
Chest-abdominopelvic CT
For chest-abdominopelvic CT, three references with DRLci were found for three clinical indications: tumour, infectious and oncologic follow-up. Table 7 shows the DRLci for chest-abdominopelvic CT with the CTDIvol and/or DLP values for each clinical indication. The DRLci for tumour and oncologic follow-up were the clinical indications with more references found (two out of three). For tumour, the DLP values ranged from 870 mGy.cm [15] to 950 mGy.cm [35]. For oncologic follow-up, the DLP values ranged from 605 mGy.cm [36] to 970 mGy.cm [34]. One publication presents DRLci for abdominal CT, both for males and females [16], demonstrating however similar values.
Table 7
DRLci for chest-abdominopelvic CT
Chest abdomen pelvis | ||||||
|---|---|---|---|---|---|---|
References | Tumour | Infectious | Oncologic follow-up | |||
CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | CTDIvol (mGy) | DLP (mGy.cm) | |
Geryes et al. (FR) 2019 [15] | 10 | 870 | 11 | 970 | 11 | 970 |
Ireland (IE) MERU 2017 [16] | – | – | – | – | 8 (a) | 605 (a) |
– | – | – | – | 8 (b) | 643 (b) | |
Norway (NO) 2018 [17] | 15 | 950 | – | – | – | – |
Discussion
To our knowledge, this is the first article to perform literature review for DRLci. Considering that DRLci is a recent concept, it is understandable that only a limited number of papers was found in the literature and most of the proposed DRLci came from the NCAs of 12 European countries.
Anzeige
In all the six anatomical areas where DRLci were found, a huge variation of CT dose descriptors values was identified, providing evidence that different approaches/protocols are used to perform the CT procedure for the same clinical indication.
In the 28 clinical indications identified in the literature, the procedures with the highest differences in DLP values were head trauma (11-fold), CCTA (9-fold), liver metastasis (3-fold) and cervical fracture (2-fold).
The huge variations in the reported CT dose descriptors values for almost all the clinical indications addressed above are likely to be explained by differences in protocols (exposure parameters and scan length), type and age of scanner, number of acquisition series and, in the specific case of CCTA, by the option of performing either prospective or retrospective acquisitions. The same variations in radiation doses for CT across patients is described in the literature, and the reasons are primarily related on how CT scanners are used [34], the differences in patient’s size (weight and height) [36] and to the level of image quality required to answer the clinical question [35]. Although the DRLs are defined for standard patients [4], taking into consideration that the weight and height of patients are also a determining factor for dose increase, categorising patients by body mass index should be considered in the near future [36].
Several other factors may also contribute to the heterogeneity of results shown in the DRLci tables. DLP values may refer to individual sequences or to a complete examination (total DLP), and in some cases, this information is not included in the paper/report.
In addition, different names have been used for what is likely to have been the same indication (e.g. abscess versus acute abdomen), and the question of whether these differences are related to various interpretations of the name of the clinical indication or to different practices remains open. A semantic refinement, with the precise description of the clinical indication, should be made in the future in order to minimise any variation related to the meaning of the clinical indication.
For liver metastases and a few other clinical indications, DRLci in terms of CTDIvol are similar, but DRLs in terms of DLP differ considerably. The difference between results in values of total DLP (yet similar levels of CTDIvol) for examinations of the lower trunk could be a consequence of the present use of increased scan lengths and/or number of sequences (particularly in relation to imaging for different phases in the distribution of contrast medium). The substantial variations in CT protocols, for the same clinical indication, delivers several folds higher radiation than necessary [33].
Although a large number of research studies have shown that dose optimisation tools such as tube current modulation can reduce patient dose considerably, it is not known how these tools are being used in everyday clinical practice. Large differences in dose descriptors for the same clinical indication and, sometimes, for the same CT scanner model may be addressed by standardising acquisition protocols, using dose reduction tools properly and improving education of practitioners in medical radiation protection.
Conclusions
From this literature review, it is obvious that there is a lot of space for improvement in terms of standardising the CT protocols for each clinical indication and that the development of European guidelines on this topic would be very useful as a tool to implement dose reduction strategies in CT procedures.
Continuing to develop DRLs for CT based in anatomical areas without taking into consideration the clinical indication will probably meet the minimum standard of the BSSD but will insufficiently contribute to fulfil the main purpose of the existence of DRLs: a tool for optimisation.
We expect that the results of this work can stimulate the radiological community and the NCAs to move toward the establishment of DRLci in a more harmonised and consistent way.
Acknowledgements
The authors would like to acknowledge Ms. Monika Hierath and Mr. Jonathan Clark, staff members of the European Society of Radiology, for their outstanding contribution to this project.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
Not applicable
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.